Table 3.
Results of meta-analysis of studies comparing linezolid with daptomycin for the treatment of VRE-BSI
| Outcomea | No. of studies | No. of patients | ORb | 95% CI | P value |
|---|---|---|---|---|---|
| Mortality | 9 | 1,074 | 1.3 | 0.996–1.8 | 0.053 |
| Inpatient | 4 | 333 | 1.7 | 1.1–2.8 | 0.08 |
| 30-Day | 3 | 271 | 1.3 | 0.9–2.3 | 0.20 |
| Microbiologic cure | 5 | 517 | 1.0 | 0.4–1.7 | 0.95 |
| Clinical cure | 3 | 357 | 1.2 | 0.5–2.1 | 0.68 |
a
Outcomes of linezolid versus daptomycin treatment were as defined by the investigation.
b
Odds ratios greater than 1 favor linezolid treatment, and odds ratios less than 1 favor daptomycin treatment. For the paper by Lu et al. (42), the 14-day mortality numbers were used for the calculation of the mortality odds ratio. Analysis using the 28-day mortality was not significantly different.